Personalized Cancer Vaccines Ecosystem Witnessing Positive Transition Driven By Development Of Proprietary Technology Platforms Says Kuick Research. Delhi, March 2 ...

Researchers at Yale Cancer Center have made a breakthrough finding that could lead to a therapies for glioblastoma and other ...

Yale scientists have discovered a promising way to trigger immune responses against certain tumors, using a lupus-related antibody that can slip, undetected, into "cold" tumors and flip on an immune ...

The first patient has been dosed in the phase 3 TACTI-004 trial evaluating efti with Keytruda and chemotherapy for advanced ...

BDC-3042 is a proprietary agonist antibody that targets dectin-2, an immune-activating receptor expressed by tumor-associated ...

Evaxion will present new biomarker and immune data obtained from the ongoing phase 2 trial. These will further add to EVX-01’s already strong clinical data package.

Mia Love, the first Black Republican woman elected to Congress, died three years after being diagnosed with glioblastoma, a ...

Scientists involved in a recent study have expressed their 'concern' over the findings which suggest that long-term exposure ...

Ernexa Therapeutics embarks on new strategic direction, shifting the company's focus from delivering a cell therapy platform to prioritizing product development ...

Yet today, at what should be a celebration of this revolutionary technology’s potential, we find ourselves wondering about the future of mRNA research. The scientific community is watching if funding ...

BDC-4182 on track to start a clinical trial in gastric cancer in second quarter 2025BDC-3042 Phase 1 clinical trial fully enrolled the highest dose cohort with no dose-limiting toxicities (DLTs), resu ...

Fatty liver disease, medically called metabolic dysfunction-associated steatotic liver disease (MASLD), affects millions ...